Instrumented Difference-in-Differences with Heterogeneous Treatment Effects

summary

The gist

Instrumented Difference-in-Differences with Heterogeneous Treatment Effects (DIDIV) This paper introduces a novel econometric framework, Instrumented Difference-in-Differences (DIDIV)…

In short

The Instrumented Difference-in-Differences (DIDIV) framework uses variations in treatment timing as an instrument to estimate causal effects when treatments are adopted at different times across groups. It proposes a robust estimation method that overcomes limitations of traditional methods, providing more reliable results, especially when treatment effects vary by group.

Key concepts

Instrumented Difference-in-Differences (DIDIV)
A novel econometric design that uses the timing of policy adoption as an instrument to estimate causal effects. It scales a standard DID estimator by another DID estimator derived from treatment timing variation, specifically targeting the Local Average Treatment Effect on the Treated (LATET).
Cohort Specific Local Average Treatment Effect on the Treated (CLATT)
A more granular target parameter used in staggered designs with multiple time periods. It aims to estimate the average effect of a treatment for a specific group (cohort) within a particular relative time period, offering a finer level of causal detail.
Two-Way Fixed Effects Instrumental Variable (TWFEIV)
A conventional estimation method that often fails when treatment effects are not stable over multiple periods. The paper shows that TWFEIV estimates can be misleading in staggered settings, whereas the proposed DIDIV method offers a more robust solution for capturing true causal effects.
Fuzzy DID Design
An alternative design where identifying the SLATET requires imposing a strong assumption about stable treatment effects. The paper compares it to DID-IV, noting that Fuzzy DID may be less policy-relevant and relies on assumptions that are harder to test with available data.

Terminology used across episodes

This episode discusses

The paper

Instrumented Difference-in-Differences with Heterogeneous Treatment Effects · Read on arXiv

Sho Miyaji

Yale University

Transcript

Introduction to the show: ident: Economics. The day in economics: theory, mechanisms and the evidence beneath them.

Ruth: I'm Ruth.

Warren: And I'm Warren, here with Iris.

Ruth: We're looking at the paper: "Instrumented Difference-in-Differences with Heterogeneous Treatment Effects".

Warren: Here's the gist of the paper. Detailed Research Summary: Instrumented Difference-in-Differences with Heterogeneous Treatment Effects (DIDIV) This paper introduces a novel econometric framework, Instrumented Difference-in-Differences (DIDIV), designed to consistently estimate causal effects in settings where treatment adoption is potentially endogenous over time.

Ruth: The core innovation lies in leveraging variation in the *timing* of policy adoption across units as an instrumental variable for the treatment itself.

Warren: Core Methodology and Target Parameters The paper formalizes the DIDIV design by using a Wald-DID estimand, which scales the standard Difference-in-Differences (DID) estimator by another DID estimand derived from the treatment timing variation.

Ruth: This specific combination is designed to capture the Local Average Treatment Effect on the Treated (LATET).

Title and authors: Ruth: So we're looking at this paper today called "Instrumented Difference-in-Differences with Heterogeneous Treatment Effects". We'll talk about what it means for causal inference in settings where things start happening at different times.

Warren: Yeah, the title itself tells you a lot about the complexity they’re tackling here, especially with those heterogeneous treatment effects they mention. It sounds like they’re trying to figure out how to measure things when not everyone gets the treatment at once or even in a fixed way.

Iris: It seems like their main goal is to get a consistent estimate of what we call the local average treatment effect on the treated, or LATET, even when the treatment adoption timing varies across different units. This is important because those timing variations can mess up standard difference-in-differences estimates.

Ruth: Exactly. They formalize this by using something they call a Wald difference-in-differences estimand which scales the outcome estimate by another difference-in-differences estimand that comes from the treatment timing variation, which is designed to capture that LATET.

Warren: And when they move it to multiple time periods with staggered instrument adoption, this becomes a staggered difference-in-differences design aiming for what they call cohort specific local average treatment effect on the treated, or CLATT. That’s a more granular target parameter than just the general LATET.

Iris: The real technical contribution here is their proposed estimation method within these staggered designs that handles treatment effect heterogeneity robustly. They set this up to avoid known issues with traditional two-way fixed effects instrumental variable regressions, like those from Johnson and Jackson or Lundborg et al.

Ruth: That’s a big deal because those traditional methods often fail to summarize the treatment effects if the instrument's effect on the treatment or outcome isn't stable over more than two periods. This new method aims to fix that stability problem for us.

Warren: I like how they test this framework by applying it to returns to schooling in the United Kingdom, using variation in school reform timing as an instrument for education attainment. It’s a concrete example they use to show their point about the estimation failure versus their new method's success.

Iris: What’s really striking is that the conventional two-way fixed effects instrumental variable regression gives a negative estimate, suggesting it fails to capture the true effect, whereas their proposed DIDIV estimation method yields positive estimates across each relative period post-reform.

Title and authors: Ruth: That contrast is pretty telling for anyone looking at policy impacts because it shows how sensitive the result is to which estimation tool you use. It suggests that standard methods might be misleading in these staggered settings.

Warren: Moving into the comparison with Fuzzy DID designs, they point out a fundamental difference in what they are trying to measure. The paper says DIDIV focuses on LATET, while Fuzzy DID targets the switcher local average treatment effect on the treated, or SLATET.

Iris: And that difference in target parameters leads directly to different identifying assumptions. Under Fuzzy DID, you have to impose a stable treatment effect assumption for the switcher local average treatment effect, which means building average time trends for untreated potential outcomes.

Ruth: But with DIDIV designs, they only impose the parallel trends assumption on unexposed outcomes rather than those untreated potential outcomes; so the Wald difference-in-differences estimand in DIDIV doesn't require that specific assumption from Fuzzy DID.

Warren: That means if you’re trying to test parallel trends using pre-exposure period data, DIDIV designs are preferable because Assumption thirty-four and its counterparts are often hard to test under Fuzzy DID. It seems like they’re advocating for a more flexible identification strategy depending on what the researcher is actually trying to find.

Iris: So, in summary, the paper suggests that researchers should assess if the restrictions imposed by Fuzzy DID are plausible before switching to a DIDIV design where the only restriction is monotonicity with respect to the instrument. This helps figure out which design fits their causal question better.

Ruth: It sounds like they’re giving us a practical roadmap for choosing an identification strategy based on what specific causal parameter we care about, whether it's LATET or SLATET. That's really useful for anyone trying to build a robust model.

Warren: And beyond just the choice of design, the paper points out how they can improve the estimation itself by using a weighting scheme based on the share of compliers in a given relative period to construct summary causal parameters that are more plausible than what standard two-way fixed effects instrumental variable regressions produce.

Iris: That weighting scheme helps ensure robustness when treatment effects are heterogeneous across units, which is where those traditional methods really struggle and often miss parts of the picture. It makes the final estimate more reliable even when things aren't perfectly uniform.

Title and authors: Ruth: It sounds like they’re not just proposing a new way to calculate a number, but a better way to get a number that actually reflects the causal reality in messy, real-world situations with staggered adoption.

Warren: So, what we have here is this paper on "Instrumented Difference-in-Differences with Heterogeneous Treatment Effects" that shows how variation in policy timing can be used as an instrument for treatment itself. It’s a sophisticated toolkit for estimating local average treatment effects when things are staggered over time and treatments aren't uniform across units.

Iris: We’ve seen how the Wald difference-in-differences estimand captures the LATET, and we’ve discussed how they propose a robust estimation technique that fixes the limitations of two-way fixed effects instrumental variable regressions in these settings.

Ruth: The paper really drives home the point that if you're looking at policy impacts, you need to be careful about what assumptions you’re making about people changing their minds over time, and this framework helps clarify those boundaries.

Warren: It gives us a clearer way to think about when a researcher should prefer the DIDIV approach over something like Fuzzy DID based on whether they prioritize the general effect or a specific local effect.

Iris: It’s a helpful distinction because it shows that the choice of parameter—LATET versus SLATET—is what really dictates which set of identification assumptions you need to worry about meeting.

Ruth: So, to wrap up, this paper on "Instrumented Difference-in-Differences with Heterogeneous Treatment Effects" gives us a detailed econometric framework for handling staggered treatment adoption by using policy timing as an instrument. It offers a superior estimation method that handles heterogeneity better than traditional two-way fixed effects instrumental variable regressions.

Warren: And it really helps us understand how to choose between different identification strategies, like DIDIV and Fuzzy DID, based on what causal question we are actually trying to answer about the effect of a treatment in the real world.

Iris: It’s a lot of detail, but it points toward a more flexible toolkit for causal inference in complex environments where things don't happen simultaneously or uniformly.

Ruth: Yeah, it gives us a better way to approach those tricky questions about policy effects and what they mean for the people living through those changes.

The paper's summary: Ruth: So, to recap, this paper introduces something called Instrumented Difference-in-Differences, or DIDIV, which uses variation in when a treatment is adopted as an instrument to estimate causal effects even when the treatment doesn't happen at the same time for everyone.

Warren: Exactly. It’s trying to solve that timing problem where things start happening staggered across different groups and units.

Iris: The paper’s main idea is using a Wald difference-in-differences estimand, which scales the usual difference-in-differences estimate by another one derived from the timing variation itself, specifically targeting what they call the local average treatment effect on the treated, or LATET.

Ruth: It’s trying to get that LATET figure consistently, even when we know that treatment effects are not uniform across different units in our study.

Warren: And they take it further by looking at staggered designs across multiple time periods and aiming for something more specific called the cohort specific local average treatment effect on the treated, or CLATT. That’s a finer grain of detail.

Iris: The big technical thing they show is this new regression method for estimating these target parameters within those staggered designs that handles treatment effect heterogeneity robustly. They explicitly try to avoid the known trouble with traditional two-way fixed effects instrumental variable regressions that often break down when the instrument's effect isn't stable over more than two time periods.

Ruth: That stability issue is a big problem because if you use old methods, you might get a result that just doesn't actually capture what’s going on causally.

Warren: They test this framework using returns to schooling in the United Kingdom, where they use the timing of school reform as an instrument for education attainment. And they show that the conventional two-way fixed effects instrumental variable regression gives a negative estimate, which suggests it’s missing the real effect.

Iris: But their proposed DIDIV estimation method yields positive estimates across each time period after the reform, which seems much more plausible for what we expect to see causally.

Ruth: It really shows how sensitive the result is to which tool you pick when dealing with staggered adoption and different treatment effects.

Warren: Then they compare it to something called Fuzzy DID, and they highlight a major difference in what each design is trying to measure. DIDIV focuses on LATET, while Fuzzy DID targets the switcher local average treatment effect on the treated, or SLATET.

Iris: That difference in target parameter leads to different identification assumptions. Under Fuzzy DID, you have to impose a stable treatment effect assumption for the SLATET that requires building average time trends for untreated potential outcomes.

Ruth: But with DIDIV designs, they only need the parallel trends assumption on unexposed outcomes instead of those treated potential outcomes, so they don't need that specific constraint from Fuzzy DID.

Warren: This means if you’re trying to test parallel trends using data before the treatment started, DIDIV designs are better because Assumption thirty-four and its counterparts are often harder to test under Fuzzy DID.

Iris: So the paper suggests researchers should check if those restrictions from Fuzzy DID make sense before switching to a DIDIV design where the only constraint is just that the instrument has a monotonic relationship with the treatment adoption.

Ruth: It’s like they’re giving us a roadmap for choosing an identification strategy based on whether you care about the general effect or one specific local effect.

Warren: And they also show how to make their estimation better by using a weighting scheme based on the share of compliers in a given time period, which helps ensure the final estimate is more robust when treatment effects are messy across different units.

Iris: That weighting scheme really helps smooth out the results when things aren't perfectly uniform, making the final number more reliable than what standard two-way fixed effects instrumental variable regressions produce.

Ruth: So, they’re not just proposing a new calculation; they’re showing how to get a result that actually reflects the causal reality in these complex situations with staggered adoption.

Warren: It boils down to this: you use variation in policy timing as an instrument, and you get better results by choosing the right estimation technique for what you are trying to measure.

Iris: This framework helps clarify the boundaries of what assumptions you’re making about how people change their minds over time when they adopt a treatment.

Ruth: So, we’ve seen how this DIDIV approach fixes a technical hurdle in staggered designs and gives us a better way to pick the right identification strategy depending on our specific causal question.

Warren: Next up, we'll look at how these ideas apply to real-world policy questions like education and see what they actually mean for outcomes.

The paper's improvements: Tom: So, we've seen how they tackle staggered treatments using timing as an instrument, and now we're looking at the actual upgrades they propose to make that approach even better.

Ruth: The paper suggests improving the core estimation by using a stacked two stage least squares regression to estimate those cohort specific local average treatment effects on the treated, or CLATT.

Warren: That’s an improvement because it specifically handles treatment effect heterogeneity, which is what breaks traditional two-way fixed effects instrumental variable regressions.

Iris: It’s a big deal because they propose a weighting scheme based on the share of compliers in each time period to construct summary causal parameters, making the final estimate more plausible than what standard methods give you.

Ruth: So, they’re not just fixing one problem; they're building a whole new way to weight those results so they don't get skewed by non-uniform treatment effects across units.

Warren: That sounds like it could drastically reduce the risk of getting a misleading estimate from a strategy that runs on assumptions about uniformity.

Iris: And they also suggest the AI can actually determine which latent treatment adoption types are excluded by specific identification assumptions, helping us distinguish between things like DIDIV and Fuzzy DID designs.

Ruth: That’s useful because it helps us see exactly what kind of causal question we can even ask with a given design.

Warren: It lets you know if your target parameter, whether it’s LATET or SLATET, is actually identifiable under the assumptions of your chosen framework.

Iris: But there's still a limitation they flag: this whole method still relies on the parallel trends assumption being true for unexposed outcomes in a certain way, and they can't fully escape testing those assumptions using pre-exposure period data if you use the Fuzzy DID setup.

Ruth: So, while these improvements make the estimation technique stronger, they still point out that testing those core assumptions remains a sticking point for certain identification strategies.

Warren: It means you get a better number from their method, but you still have to be careful about what restrictions that method imposes on your world model.

Iris: Exactly. This isn't a magic fix; it’s an improvement in the tools available to handle complexity, but the fundamental assumptions about how people change their minds over time are still there.

Ruth: So, they give us a better estimation toolkit and a clearer way to choose your identification strategy based on what you need to find causally.

Warren: It’s all about choosing the right tool for the job, whether you prioritize the general effect or that specific local effect on treated groups.

Iris: This points toward a more flexible approach for causal inference in complex environments where things don't happen simultaneously or uniformly across different groups.

Ruth: So, they’re giving us a more robust way to look at policy impacts and what those impacts actually mean for the people who are affected by them.

Warren: Next up, we’ll look at how these ideas apply to real-world policy questions like education and see what they actually mean for outcomes.

Conclusion: Tom: So, to wrap up, this paper on "Instrumented Difference-in-Differences with Heterogeneous Treatment Effects" shows how policy timing can be used as an instrument to estimate causal effects when treatment adoption isn't uniform over time.

Ruth: The main implication is that we need more sophisticated tools than standard difference-in-differences estimators when treatments are staggered across different groups and those groups react differently.

Warren: It suggests that if you just use the conventional methods, you might be getting a number that doesn't reflect the real causal reality because it ignores how treatment effects change over time for different people.

Iris: The paper gives us a clearer way to choose between identification strategies like DIDIV and Fuzzy DID based on whether we want to find the general effect or a specific local effect on treated groups.

Ruth: So, it’s basically saying that the choice of estimation method should be driven by what kind of causal question you're actually trying to answer about the treatment.

Warren: It’s telling us that being flexible with your identification assumptions is crucial when things are happening at different times and for different people at different rates.

Iris: And they highlight that while the estimation method improves, we still have to be careful because those core parallel trends assumptions are still what ground the whole thing.

Ruth: So, we get a more robust way to calculate the effects, but we can't ignore the underlying assumptions about how people change their minds over time.

Warren: It’s a tool that helps us navigate those messy real-world situations where things don't happen at once or evenly across all units.

Iris: This paper gives us a better way to approach those tricky questions about policy effects and what they mean for the people living through those changes.

Ruth: We’ve seen how this DIDIV framework fixes a technical hurdle in staggered designs and gives us a better way to pick the right identification strategy based on our specific needs.

Warren: It boils down to using policy timing as an instrument, and then picking the right estimation technique for what you need to measure across those staggered groups.

Iris: This is a valuable piece because it shows how we can build more flexible tools for causal inference in complex environments where things don't happen simultaneously or uniformly.

Ruth: It’s a lot of detail, but it points toward a more flexible toolkit for figuring out the real impact of policy changes.

Warren: We’ll keep an eye on how this framework gets used to analyze things like education and see what they actually mean for outcomes in the next round.

More episodes

← Home